FDA approves Mersadon Keytruda and Inlyta combination therapy to treat patients with advanced renal cell cancer

recently,The FDA(http://approved a combination of Heavy Anti-PD-1 therapy Keytruda and Inlyta (axitinib) for first-line treatment for patients with advanced renal cell carcinoma (RCC)the second immunocheckpoint inhibitor combination therapy has been approved as a first-line therapy for advanced RCC treatments, following the FDA-approved late-stage RCC for nivolumab and ipilimumab last yearaboutKeytruda is an anti-PD-1 monoclonal antibody that improves the body's immune system's ability to detect and kill tumor cells by preventing PD-1 from binding to its ligands PD-L1 and PD-L2Inlyta, a TKI developed by Pfizer'scompany(http://, inhibits the activity of VEGFR1-3 and limits tumor growth by inhibiting vascular proliferationIt has been approved by the FDA as a second-line therapy treatment for RCCThe Keytruda/Inlyta combination has been awarded by the FDA for breakthrough therapy accreditation and priority review for advanced RCC treatmentsThis approval is based on the results of keytruda combination therapy in a randomized double-blind, active-controlled phase 3 clinicaltrial(http://) results In the trial, 861 advanced RCC patients were randomly divided into two groups and received a combination of Keytruda and Inlyta, or sunitinib the scheduled medium-term analysis (http:// results show that keytruda/Inlyta combination therapy reduced the patient's risk of death by 47% (HR -0.53; 95% CI: 0.38, 0.74; p 0.0001 The total survival rate after 12 months of treatment in the Keytruda/Inlyta group was 90% and the active control group was 78% Keytruda/Inlyta combination therapy also significantly increased the patient's progression survival (15.1 months vs 11.1 months, p.0001
.